Nathaniel Marchetti, DO
Pulmonary Disease · Philadelphia, PANPI 1285622233
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AstraZeneca at 50.3% of the total. 2025 is the largest year on record at $10,149, 3.0 times the $3,370 reported in 2020. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $793.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- CSL Behring$4K
- Astrazeneca UK Limited$2K
- Chiesi USA, Inc.$2K
- Verona Pharma, Inc.$2K
- Pulmonx Corporation$609
- plus $74 from 3 others
Across 73 payments — averaging $2722.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$81K
- Vertex$42K
- Galvanize Therapeutics, Inc$32K
- Boehringer Ingelheim$17K
- Sanofi US Services Inc.$15K
- Chiesi USA, Inc.$11K
- plus $110 from 1 others
What the payments were for
- Consulting fees$12,66059%
- Speaking & faculty fees$6,37230%
- Travel & lodging$1,9479%
- Food & beverage$4472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $10,775 |
| CSL Behring | 3 | $4,032 |
| Astrazeneca UK Limited | 2 | $2,325 |
| Chiesi USA, Inc. | 2 | $2,111 |
| Verona Pharma, Inc. | 1 | $1,500 |
| Pulmonx Corporation | 5 | $609 |
| Endovascular Engineering Inc. | 1 | $44 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$4,600
- BREZTRI AEROSPHERE$3,370
- Zemaira$2,867
- Ohtuvayre$1,500
- ZEPHYR ENDOBRONCHIAL VALVE$400
How this compares
$21,426 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 161 | $2,045,049 |
| Tyvaso DpiTreprostinil | 43 | $1,113,231 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $798,409 |
| Dupixent PenDupilumab | 65 | $261,667 |
| PrevymisLetermovir | 35 | $257,251 |
| Pirfenidone | 36 | $168,527 |
| NucalaMepolizumab | 25 | $158,794 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 176 | $146,601 |
| Atovaquone | 219 | $118,250 |
| Ambrisentan | 20 | $83,524 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 108 | $82,639 |
| Spiriva RespimatTiotropium Bromide | 106 | $67,413 |
| EliquisApixaban | 72 | $61,488 |
| XolairOmalizumab | 14 | $46,977 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $45,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra | $10,775 | $114,867192 claims |
| CSL BehringPrivigen | $4,032 | $45,01312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.